Effect of lung-volume-reduction surgery in patients with severe emphysema.
BACKGROUND
Although many patients with severe emphysema have undergone lung-volume-reduction surgery, the benefits are uncertain. We conducted a randomized, controlled trial of the surgery in patients with emphysema. Patients with isolated bullae were excluded because such patients are known to improve after bullectomy.


METHODS
Potentially eligible patients were given intensive medical treatment and completed a smoking-cessation program and a six-week outpatient rehabilitation program before random assignment to surgery or continued medical treatment. After 15 patients had been randomized, the entry criteria were modified to exclude patients with a carbon monoxide gas-transfer value less than 30 percent of the predicted value or a shuttle-walking distance of less than 150 m, because of the deaths of 5 such patients (3 treated surgically and 2 treated medically).


RESULTS
Of the 174 subjects who were initially assessed, 24 were randomly assigned to continued medical treatment and 24 to surgery. At base line in both groups, the median forced expiratory volume in one second (FEV1) was 0.75 liter, and the median shuttle-walking distance was 215 m. Five patients in the surgical group (21 percent) and three patients in the medical group (12 percent) died (P=0.43). After six months, the median FEV1 had increased by 70 ml in the surgical group and decreased by 80 ml in the medical group (P=0.02). The median shuttle-walking distance increased by 50 m in the surgical group and decreased by 20 m in the medical group (P=0.02). There were similar changes on a quality-of-life scale and similar changes at 12 months of follow-up. Five of the 19 surviving patients in the surgical group had no benefit from the treatment.


CONCLUSIONS
In selected patients with severe emphysema, lung-volume-reduction surgery can improve FEV1, walking distance, and quality of life. Whether it reduces mortality is uncertain.
Geddes
D
D
Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom.
Davies
M
M
Koyama
H
H
Hansell
D
D
Pastorino
U
U
Pepper
J
J
Agent
P
P
Cullinan
P
P
MacNeill
S J
SJ
Goldstraw
P
P
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D004646:Emphysema / Q000145:classification / Q000503:physiopathology / Q000601:surgery* / Q000628:therapy; D017079:Exercise Tolerance; D005541:Forced Expiratory Volume; D006801:Humans; D011013:Pneumonectomy; D011788:Quality of Life; D016540:Smoking Cessation; D014109:Total Lung Capacity
D000318:Adrenergic beta-Agonists